IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX) is a healthcare company (diagnostics & research) based in the United States. The share price is $695.48, down 0.74% on the day, which values the company at $54.79B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.

Key facts

Share price
$695.48−0.74% today
Market value
$54.79B
P/E ratio
46.9×last 12 months
Forward P/E
41.2×
Funk Score
67/100
Against its own history
Above its usual priceusual price $552.14
200-week average
$526.7732% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

IDEXX Laboratories, Inc. in more detail

IDXX trades at 46.9× its last twelve months' earnings, 41.2× next year's expected earnings, 11.8× sales. Measured against its own history, the price is 26% above what its usual multiples would imply ($552.14) — above its usual price. It sits 32% above its 200-week average of $526.77.

Over the last five fiscal years IDEXX Laboratories, Inc. has compounded revenue 9.7% a year, earnings per share 14.3% a year, free cash flow 14.0% a year. Its Funk Score is 67 out of 100 (financial strength 8.0, profitability 9.4, growth 6.9, value 2.4, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

10 of the superinvestors tracked here hold IDXX, including Terry Smith (2.9% of the portfolio), Polen Capital team (2.2% of the portfolio), Jensen team (1.8% of the portfolio).

Superinvestors holding IDXX

10 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:IDXX vs MDLN (IDEXX Laboratories, Inc. vs Medline)IDXX vs BDX (IDEXX Laboratories, Inc. vs Becton, Dickinson)IDXX vs EW (IDEXX Laboratories, Inc. vs Edwards Lifesciences)IDXX vs ARGX (IDEXX Laboratories, Inc. vs argenx)IDXX vs HUM (IDEXX Laboratories, Inc. vs Humana)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

IDEXX Laboratories, Inc. (IDXX): questions and answers

What is IDXX's P/E ratio?

IDEXX Laboratories, Inc. trades at 46.9× its last twelve months' earnings and 41.2× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 19.3× to 76.6×, with a median of 42.5×.

What is IDXX's PEG ratio?

IDEXX Laboratories, Inc.'s PEG ratio is 3.27 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is IDEXX Laboratories, Inc.'s market cap?

IDEXX Laboratories, Inc. is valued at $54.79B at a share price of $695.48.

Is IDXX overvalued or undervalued?

Against its own history, IDXX is above its usual price: the price is 26% above the $552.14 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is IDXX above its 200-week moving average?

Yes. IDXX is 32.0% above its 200-week average of $526.77. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is IDEXX Laboratories, Inc. growing?

Over the last five fiscal years IDEXX Laboratories, Inc.'s revenue grew 9.7% a year and its earnings per share 14.3% a year; over ten years revenue grew 10.4% a year.

Cite this page

Funkfolio, “IDEXX Laboratories, Inc. (IDXX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IDXX

Underlying data: Yahoo Finance; company filings with the SEC.